As of June 3, 2025, Oragenics Inc (OGEN) reports a ROA (Return on Assets) of -717.68%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Oragenics Inc's ROA (Return on Assets)
Over recent years, Oragenics Inc's ROA (Return on Assets) has shown a stable trend. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2024-12-31 | -717.68% |
| 2023-12-31 | -415.91% |
| 2022-12-31 | -96.82% |
| 2021-12-31 | -55.65% |
| 2020-12-31 | -141.49% |
This slight downward trend highlights how Oragenics Inc manages its efficiency in using assets to generate earnings over time.
Comparing Oragenics Inc's ROA (Return on Assets) to Peers
To better understand Oragenics Inc's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Oragenics Inc (OGEN) | -717.68% |
| Liminal BioSciences Inc (LMNL) | 0.99% |
| PharmaCyte Biotech Inc (PMCB) | 0.56% |
| Forward Pharma A/S (FWP) | -2.65% |
| ARCA Biopharma Inc (ABIO) | -14.10% |
| Sunshine Biopharma Inc (SBFM) | -16.80% |
Compared to its competitors, Oragenics Inc's ROA (Return on Assets) is among the lowest compared to peers, suggesting potential inefficiency in asset utilization.